. Author manuscript; available in PMC: 2015 Oct 30.

Published in final edited form as: Brain Disord Ther. 2015 Jul 18;Suppl 2:005. doi: 10.4172/2168-975X.S2-005

Table 1.

Recent clinical successes and developments of AZD6244 (selumetinib) and PLX4032 (vemurafenib).

Small Molecule Inhibitor	Molecular Target	Patient Eligibility	Clinical Trial Phase
Dabrafenib	BRAF^V600E	BRAF^V600E mutations in HGGs, LGGs, etc.	Phase 1
Vemurafenib	BRAF^V600E	Children with recurrent or refractory glioma	Phase 1/2
Selumetinib	MEK1/2	Recurrent or refractory low-grade pediatric gliomas	Phase 1/2
Selumetinib + docetaxel	MEK1/2	KRAS-mutated NSCLC	Phase 2
Selumetinib	MEK1/2	mutated BRAF cancers	Phase 2
Dabrafenib + Trametinib	BRAF^V600E + MEK1/2	LGGs, HGGs, etc.	Phase 2
Sorafenib	Multikinase inhibitor	Low-grade astrocytomas	Phase 2 (Terminated)